文献速递胸部肿瘤放疗消化道肿瘤放疗

胸段食管癌容积调强弧形放疗的剂量学与临床结局

Dosimetric and clinical outcomes after volumetric modulated arc therapy for carcinoma of the thoracic esophagus.
PubMed 文献 · Adv Radiat Oncol · 2017-03-27

该单中心回顾性研究分析了65例接受VMAT同步化疗的胸段食管癌患者,并通过倾向性评分匹配与130例ssIMRT患者比较。VMAT靶区适形性更优,而危及器官保护、生存率、复发率及毒性反应与ssIMRT相当,提示VMAT安全有效。

要点

  • VMAT靶区适形性优于ssIMRT,心脏V5较高但V50较低,其余剂量学指标相似。
  • 两组1年、2年总生存率和无复发生存率均无显著差异。
  • 病理完全缓解率及毒性反应、术后并发症在两组间无显著差异。

核心结论

  • 与ssIMRT相比,VMAT靶区适形性更好,危及器官保护相似,生存、复发和毒性结局相当,提示VMAT治疗食管癌安全有效。

研究设计与样本

  • 单中心回顾性分析65例接受VMAT(50.4 Gy,范围45-50.4 Gy)同步化疗的胸段食管癌患者,并用倾向性评分匹配130例接受ssIMRT同步化疗的患者。

主要发现

  • VMAT适形指数高于ssIMRT(87.75 ± 10.70 vs 83.20 ± 9.42,P = .003),心脏V5较高、V50较低,而肺V5-20、心脏V30、心脏V40、脊髓最大剂量和均匀性指数相似。
  • VMAT组中位随访14.3个月(范围3.8-34.5个月),ssIMRT组31.8个月(范围1.8-117.2个月);1年总生存率93.5% vs 91.5%,2年60.0% vs 61.4%(P = .868)。
  • 1年无复发生存率73.3% vs 79.5%,2年59.9% vs 61.8%(P = .614);病理完全缓解率31.2% vs 23.3%(P = .41)。
  • 放射性肺炎9% vs 15.4%,心包积液2% vs 7%,食管瘘和狭窄9% vs 13%,所有毒性及术后并发症P > .05。

临床怎么用

  • VMAT可作为胸段食管癌同步放化疗的放疗技术选择,靶区适形性更优且毒性可控。

局限性

  • 回顾性单中心设计,VMAT组随访时间短于ssIMRT组,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The efficiency of radiation delivery via volumetric modulated arc therapy (VMAT) is indisputable, but outcomes after VMAT for thoracic esophageal carcinoma are largely unknown. METHODS AND MATERIALS: We retrospectively analyzed 65 patients with thoracic esophageal cancer who received VMAT to 50.4 Gy (range, 45-50.4 Gy) with concurrent chemotherapy from November 2012 to March 2016 at a single tertiary cancer center. We then used propensity score matching to match these 65 patients with 130 other patients treated with step-and-shoot intensity modulated radiation therapy (ssIMRT) and concurrent chemotherapy. Differences in continuous and categorical variables were examined with independent-sample t or Wilcoxon tests and χ2 tests. RESULTS: Dosimetrically, VMAT had a higher conformity index (87.75 ± 10.70 VMAT vs 83.20 ± 9.42 ssIMRT, P = .003), a higher heart V5, and a lower V50 than ssIMRT, but lung V5-20, heart V30, heart V40, cordmax, and homogeneity index were similar. At median follow-up intervals of 14.3 months (range, 3.8-34.5 months) for VMAT and 31.8 months (range, 1.8-117.2 months) for ssIMRT, overall survival rates were similar between the treatments (93.5% VMAT vs 91.5% ssIMRT at 1 year; 60.0% VMAT and 61.4% ssIMRT at 2 years; P = .868). Recurrence-free survival rates were similar (73.3% VMAT vs 79.5% ssIMRT at 1 year, 59.9% VMAT and 61.8% ssIMRT at 2 years; P = .614), as were pathologic complete response rates (31.2% VMAT vs 23.3% ssIMRT; P = .41) and toxicity and postoperative complications (radiation pneumonitis 9% VMAT vs 15.4% ssIMRT; pericardial effusion 2% VMAT vs 7% ssIMRT; esophageal fistula and stricture 9% VMAT vs 13% ssIMRT; all P > .05). CONCLUSION: Compared with ssIMRT, VMAT had better target conformity with similar organ sparing and comparable rates of survival, recurrence, and toxicity. These results suggest that VMAT can be safe and effective for esophageal cancer.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Xu C, Xi M, Komaki R, et al. Dosimetric and clinical outcomes after volumetric modulated arc therapy for carcinoma of the thoracic esophagus. Adv Radiat Oncol. 2017. PMID: 29114599. doi:10.1016/j.adro.2017.03.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。